3 Best Value Stocks with Over 10% Upside in 2026, According to Analysts

Value stocks are shares of companies that appear undervalued relative to their fundamentals. This means their stock price looks low compared with what the business earns, owns, or is expected to generate in the future. They often come from mature, financially stable companies with steady cash flow, consistent profits, and strong balance sheets.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Value stocks tend to have lower valuation ratios, such as low price‑to‑earnings (P/E) or price‑to‑book (P/B) ratios, suggesting the market may be underpricing the company.

Now, let’s check the three value stocks that analysts have spotlighted. Each offers more than 10% upside potential from current levels.

Here Are This Week’s Stocks

****SkyWest ****SKYW -0.65% ▼ – SkyWest operates a regional airline in the United States. It has a Strong Buy analyst consensus rating and an average price target of $128.50, implying an 18.20% upside potential from the current levels. The company’s P/E of 9.83x reflects a 63.9% discount to the Industrials sector’s median of 27.24.

The company reported better-than-expected Q4 results on January 30. The airline benefited from rising travel demand and its expanded E175 fleet under new multi‑year contracts.

Newmont Mining NEM -7.92% ▼ – This gold mining company produces gold and other metals across North and South America, Australia, and Africa. Its average price target of $148.26 implies a 15.17% upside potential from the current levels. NEM stock has a Strong Buy consensus rating. Trading at a P/E of 20.33x, the company is valued 17.8% below the Basic Materials sector’s median multiple of 24.72.

Last week, Newmont said it will invest $800 million to expand its Cerro Negro project in Argentina, strengthening its long‑term production pipeline and deepening its presence in the region.

Regeneron Pharmaceuticals REGN -2.51% ▼  – This biotechnology company develops innovative antibody-based therapies for serious diseases, including cancer, eye conditions, and inflammatory disorders. It has a Strong Buy analyst consensus rating and an average price target of $873.14, implying an 11.7% upside potential from the current levels. With a P/E ratio of 18.84x, the stock is priced at a 27.6% discount to the Healthcare sector’s median of 26.03.

Last week, Regeneron and Sanofi SNY -2.40% ▼ said the FDA has approved Dupixent for treating allergic fungal rhinosinusitis in patients 6 and older with a history of sino‑nasal surgery, expanding its U.S. indications in sino‑nasal diseases.

Disclaimer & DisclosureReport an Issue